Literature DB >> 30303521

To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation.

Ching-Hon Pui1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30303521      PMCID： PMC6289752          DOI： 10.1002/cncr.31756

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  20 in total

1.  Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.

Authors:  Kazutaka Yamaji; Tomomi Okamoto; Shohei Yokota; Arata Watanabe; Yasuo Horikoshi; Keiko Asami; Atsushi Kikuta; Nobuyuki Hyakuna; Yutaka Saikawa; Junichi Ueyama; Tsutomu Watanabe; Masahiko Okada; Takashi Taga; Hirokazu Kanegane; Kazuhiro Kogawa; Motoaki Chin; Asayuki Iwai; Takeshi Matsushita; Yasuto Shimomura; Toshinori Hori; Masahito Tsurusawa
Journal:  Pediatr Blood Cancer       Date:  2010-12-15       Impact factor: 3.167

2.  Delay of the diagnostic lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia who undergo routine corticosteroid testing: Tokyo Children's Cancer Study Group study L89-12.

Authors:  A Manabe; M Tsuchida; R Hanada; K Ikuta; Y Toyoda; Y Okimoto; K Ishimoto; H Okawa; A Ohara; T Kaneko; K Koike; T Sato; K Sugita; F Bessho; Y Hoshi; M Maeda; A Kinoshita; T Saito; Y Tsunematsu; S Nakazawa
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

3.  Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Authors:  Ching-Hon Pui; Deqing Pei; Elaine Coustan-Smith; Sima Jeha; Cheng Cheng; W Paul Bowman; John T Sandlund; Raul C Ribeiro; Jeffrey E Rubnitz; Hiroto Inaba; Deepa Bhojwani; Tanja A Gruber; Wing H Leung; James R Downing; William E Evans; Mary V Relling; Dario Campana
Journal:  Lancet Oncol       Date:  2015-03-20       Impact factor: 41.316

4.  Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation.

Authors:  Meng-Ju Li; Hsi-Che Liu; Hsiu-Ju Yen; Tang-Her Jaing; Dong-Tsamn Lin; Chao-Ping Yang; Kai-Hsin Lin; Iou-Jih Hung; Shiann-Tarng Jou; Meng-Yao Lu; Chih-Cheng Hsiao; Ching-Tien Peng; Tai-Tsung Chang; Shih-Chung Wang; Ming-Tsan Lin; Jiann-Shiuh Chen; Te-Kau Chang; Giun-Yi Hung; Kang-Hsi Wu; Yung-Li Yang; Hsiu-Hao Chang; Shih-Hsiang Chen; Ting-Chi Yeh; Chao-Neng Cheng; Pei-Chin Lin; Shyh-Shin Chiou; Jiunn-Ming Sheen; Shin-Nan Cheng; Shu-Huey Chen; Yu-Hsiang Chang; Wan-Ling Ho; Yu-Hua Chao; Rong-Long Chen; Bow-Wen Chen; Jinn-Li Wang; Yuh-Lin Hsieh; Yu-Mei Liao; Shang-Hsien Yang; Wan-Hui Chang; Yu-Mei Y Chao; Der-Cherng Liang
Journal:  Pediatr Blood Cancer       Date:  2016-10-03       Impact factor: 3.167

Review 5.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.

Authors:  Carine Domenech; Stefan Suciu; Barbara De Moerloose; Françoise Mazingue; Geneviève Plat; Alina Ferster; Anne Uyttebroeck; Nicolas Sirvent; Patrick Lutz; Karima Yakouben; Martine Munzer; Pierre Röhrlich; Dominique Plantaz; Frederic Millot; Pierre Philippet; Nicole Dastugue; Sandrine Girard; Hélène Cavé; Yves Benoit; Yves Bertrandfor
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

7.  Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Authors:  Anja Möricke; Martin Zimmermann; Maria Grazia Valsecchi; Martin Stanulla; Andrea Biondi; Georg Mann; Franco Locatelli; Giovanni Cazzaniga; Felix Niggli; Maurizio Aricò; Claus R Bartram; Andishe Attarbaschi; Daniela Silvestri; Rita Beier; Giuseppe Basso; Richard Ratei; Andreas E Kulozik; Luca Lo Nigro; Bernhard Kremens; Jeanette Greiner; Rosanna Parasole; Jochen Harbott; Roberta Caruso; Arend von Stackelberg; Elena Barisone; Claudia Rössig; Valentino Conter; Martin Schrappe
Journal:  Blood       Date:  2016-02-17       Impact factor: 22.113

Review 8.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia.

Authors:  Ching-Hon Pui; Scott C Howard
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

9.  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:  Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

10.  Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

Authors:  Anjo J Veerman; Willem A Kamps; Henk van den Berg; Eva van den Berg; Jos P M Bökkerink; Marrie C A Bruin; Marry M van den Heuvel-Eibrink; Carin M Korbijn; Elisabeth T Korthof; Karin van der Pal; Theo Stijnen; Margreet H van Weel Sipman; J Fransje van Weerden; Elisabeth R van Wering; Anna van der Does-van den Berg
Journal:  Lancet Oncol       Date:  2009-09-09       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.